ReviewInfection and drug resistance2021
Managing Fungal Infections in Cystic Fibrosis Patients: Challenges in Clinical Practice.
Review in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Severe Hypoxia Reduces Adenylyl Cyclase 6 Expression and Function in Bronchial Epithelial Cells.FASEB bioAdvances · 2026Article
- Beyond colonization: Candida albicans exhibits substantial pathogenic potential in cystic fibrosis environments.NPJ biofilms and microbiomes · 2025Article
- Exploring the bioactive landscape: peptides and non-peptides from the human microbiota.NPJ biofilms and microbiomes · 2025Review
- Prevalence and clinical impact of bacterial co-infection in chronaturenic pulmonary aspergillosis.BMC pulmonary medicine · 2025Observational
- Access to Substituted Tricyclic Heteroarenes by an Oxidative Cyclization Reaction and Their Antifungal Performance.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Confronting the Fungus among Us in the Airways of People with Cystic Fibrosis.Annals of the American Thoracic Society · 2025Article
- Influence of Fungal Colonization on Exacerbations in Patients with Cystic Fibrosis.Journal of fungi (Basel, Switzerland) · 2024Article
- Drivers of diversification in fungal pathogen populations.PLoS pathogens · 2024Review
- Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?ACS applied materials & interfaces · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic Fibrosis (CF) is an autosomal recessive disease characterized by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Impairment of the CFTR protein in the respiratory tract results in the formation of thick mucus, development of inflammation, destruction of bronchial tissue, and development of bacterial or fungal infections over time. CF patients are commonly colonized and/or infected with fungal organisms,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.